ROIV - Public offerings

H.C. Wainwright & Co., LLC, a full-service investment bank dedicated to providing corporate finance, strategic advisory, and equity research coverage to public and private companies across multiple sectors and regions, is pleased to announce the following keynote speakers and Bitcoin Mining Panel as part of its 26th Annual Global Investment Conference, September 9-11, 2024 at the Lotte New York Palace Hotel. Vivek Ramaswamy, Founder, Roivant Sciences, Ltd. (NASDAQ:ROIV); Co-Founder, Strive Asset Management; Partner, QVT Financial LP; and former U.S. presidential candidate will deliver his keynote address at 4:00 p.m. Eastern Time on Monday, September 9. On Tuesday, September 10, preemin

Roivant entered into a definitive agreement with Roche for the sale of Telavant for $7.1B upfront and a milestone payment of $150M payable upon the initiation of a Phase 3 trial in ulcerative colitisIMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab, based on initial results from Phase 1 single-ascending dose and 300 mg multiple-ascending dose studiesIMVT-1402 showed no statistically significant dose-related decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohortVTA

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (NASDAQ:ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Wednesday, March 15 to review topline results from the ADORING 2 study, one of two replicate Phase 3 studies in atopic dermatitis. To access the call by phone, please register online using this registration link. A webcast of the call will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the call. About Roivant Sciences Ro

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (NASDAQ:ROIV) today announced that its founder Vivek Ramaswamy has stepped down from the company's board of directors to focus on his U.S. presidential campaign. Vivek founded Roivant in 2014 with the vision of revolutionizing drug development. Over the past decade, the FDA has granted six FDA approvals for medicines developed at Vants launched by Roivant, including VTAMA, approved for plaque psoriasis in 2022. In January 2021, Vivek transitioned out of his day-to-day role as CEO of the company. He served as Roivant's Chairman until February 20, 2023. "On behalf of the entire compan

$9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions written by approximately 8,600 unique prescribers since launchVTAMA payor coverage significantly expanded, with 57% of commercial lives now coveredADORING 1 and 2 trials evaluating tapinarof in atopic dermatitis fully enrolled, with topline data expected from the first study in March 2023 and the second study in May 2023Partnership established with Pfizer to develop RVT-3101, a potentially first-in-class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A)Statistically significant and clinically meaningful efficacy results repor

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (NASDAQ:ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common shares at a price to the public of $7.50 per share. All of the common shares to be sold in the offering are to be sold by Roivant. The gross proceeds to Roivant from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $200 million. In addition, Roivant has granted the underwriters a 30-day option to purchase up to an additional 3,999,999 common shares on the same terms and conditions. The offering is expec

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (NASDAQ:ROIV) announced today that it has commenced an underwritten public offering of $150 million of common shares. In addition, Roivant expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of common shares. All of the common shares are being offered by Roivant. The proposed offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (NASDAQ:ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the pricing of its primary and secondary public offering of 30,000,000 common shares of Roivant, consisting of 20,000,000 common shares offered by Roivant and 10,000,000 common shares offered by the selling shareholders at a price to the public of $5.00 per share for total gross proceeds of $150 million, consisting of total gross proceeds to Roivant of approximately $100 million and total gross proceeds to the selling shareholders of approximate

BASEL, Switzerland, LONDON, NEW YORK, and BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (NASDAQ:ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten public offering of $150,000,000 of common shares. Roivant expects to grant the underwriter a 30-day option to purchase up to $22.5 million of additional common shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Cantor Fitzgerald & Co. is acting as sole b